A comparison of high-flow nasal cannula and standard facemask as pre-oxygenation technique for general anesthesia

A PRISMA-compliant systemic review and meta-analysis

Hsien-Cheng Kuo, MD\textsuperscript{a,b}, Wan-Chi Liu, MD\textsuperscript{a,b}, Chun-Cheng Li, MD\textsuperscript{a,b}, Yih-Giun Cherng, MD, MSc\textsuperscript{a,b}, Jui-Tai Chen, MD, PhD\textsuperscript{a,b}, Hsiang-Ling Wu, MD\textsuperscript{c,d}, Ying-Hsuan Tai, MD, MSc\textsuperscript{a,b,}\footnote{Correspondence: Ying-Hsuan Tai, Department of Anesthesiology, Shuang Ho Hospital, Taipei Medical University, No.291, Zhongzheng Rd., Zhonghe District, New Taipei City, 23561, Taiwan (e-mail: 18045@s.tmu.edu.tw).}

Abstract

Background: Current practice guidelines recommend the use of nasal cannula as an alternative pre-oxygenation method for tracheal intubation. However, the efficacy of high-flow nasal oxygenation versus standard facemask oxygenation has not been fully evaluated.

Methods: We searched PubMed, Cochrane Library, and ClinicalTrials.gov for English-language studies published from January 1, 2000 to November 30, 2021. We included randomized controlled trials which compared high-flow nasal oxygenation and facemask oxygenation as the pre-oxygenation maneuver. Primary outcome was arterial partial pressure of oxygen (PaO\textsubscript{2}) after pre-oxygenation. Secondary outcomes were safe apnea time, arterial desaturation during intubation, lowest peripheral capillary oxygen saturation during intubation, and patient comfort score. Random-effects models and Mantel–Haenszel method were used for data synthesis.

Results: A total of 16 randomized controlled trials and 1148 patients were included. High-flow nasal oxygenation achieved a higher PaO\textsubscript{2} compared with facemask, mean difference: 64.86 mm Hg (95\% confidence interval [CI]: 32.33–97.40, \(P < .0001\)). Safe apnea time was longer in high-flow nasal oxygenation, mean difference: 131.03 seconds (95\% CI: 59.39–202.66, \(P < .0001\)). There was no difference in the risk of peri-intubation desaturation or lowest peripheral capillary oxygen saturation between groups. Patient comfort score was higher in high-flow nasal oxygenation, mean difference: 1.00 (95\% CI: 0.46–1.54, \(P = .0003\)).

Conclusion: High-flow nasal oxygenation better enhanced PaO\textsubscript{2} and extended safe apnea time and is not inferior to facemask oxygenation in preventing desaturation during tracheal intubation. High-flow nasal oxygenation may be considered as an alternative method, especially for patients with a potential difficult airway.

Abbreviations: CI = confidence interval, FMO = facemask oxygenation, GA = general anesthesia, HFNO = high-flow nasal oxygenation, PaO\textsubscript{2} = arterial partial pressure of oxygen, PEEP = positive end-expiratory pressure, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses, RR = risk ratio, SpO\textsubscript{2} = peripheral capillary oxygen saturation.

Keywords: apneic oxygenation, difficult airway, high-flow nasal oxygenation, transnasal humidified rapid-insufflation ventilatory exchange

Editor: Ahmet Eroglu.

This work was supported by the grants from Taipei Medical University (TMU110-AE1-B11), Taipei, Taiwan and Ministry of Science and Technology (MOST109-2314-B-038-024), Taipei, Taiwan.

The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

The datasets generated during and/or analyzed during the current study are publicly available.

\textsuperscript{a} Department of Anesthesiology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, \textsuperscript{b} Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, \textsuperscript{c} Department of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan, \textsuperscript{d} School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Copyright \textcopyright 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kuo HC, Liu WC, Li CC, Cherng YG, Chen JT, Wu HL, Tai YH. A comparison of high-flow nasal cannula and standard facemask as pre-oxygenation technique for general anesthesia: a PRISMA-compliant systemic review and meta-analysis. Medicine 2022;101:10(e28903).

Received: 4 February 2021 / Received in final form: 9 December 2021 / Accepted: 3 February 2022

http://dx.doi.org/10.1097/MD.00000000000028903
1. Introduction

Pre-oxygenation before induction of anesthesia is an established procedure to increase the oxygen reservoir in the lungs, to delay the occurrence of desaturation, and to allow more time for laryngoscopy and tracheal intubation.[1] This is particularly important for patients who have poor underlying physiological reserve or undergo rapid sequence induction.[2] Pre-oxygenation is typically performed using a facemask with an adequate seal between the patient and the circuit to deliver oxygen. This standard method has been shown to extend the safe apnea time to 6 minutes for securing the airway in anesthetized patients.[3]

Difficult Airway Society 2015 guidelines recommend the use of simple nasal cannula as an alternative method to deliver oxygen continuously during induction of anesthesia.[4] Currently, high-flow nasal cannula is widely used to deliver warmed and humidified oxygen flow at a rate over 60 L/minute.[5] Study has shown that high-flow nasal oxygenation (HFNO) generates positive pressure and facilitates carbon dioxide clearance in anesthetized and apneic patients.[6,7] However, it remains uncertain whether HFNO is more efficacious in enhancing arterial oxygenation or reducing peri-intubation desaturation compared with standard facemask oxygenation (FMO). This controversy is potentially due to the study limitations of previous studies, including small sample sizes and discrepancies in oxygenation protocol.[8–23] Recent meta-analyses focused on the efficacy of HFNO in critically ill patients with acute respiratory failure.[24,25] However, these results cannot be generalized to anesthetized patients due to the obvious difference in patients’ health condition and clinical setting.

To better clarify the role of HFNO in pre-oxygenation for general anesthesia (GA), we collected the available published data from randomized controlled trials and conducted this meta-analysis to compare the oxygenation level, safe apnea time, and peri-intubation arterial desaturation between HFNO and FMO as the pre-oxygenation method. Based on previous evidence,[4–7] we hypothesized that HFNO better enhances the level of arterial blood oxygen, prolongs safe apnea time, and reduces the risk of desaturation during intubation in comparison with conventional FMO.

2. Methods

2.1. Data sources and searches

This meta-analysis used the aggregate data from published studies, did not directly involve human subjects, and therefore did not require the approval of institutional review board. We used the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines[26] and performed a comprehensive search using PubMed, Cochrane Library, and ClinicalTrials.gov for published studies in English from January 1, 2000 to November 30, 2021. We searched with the keywords “high-flow nasal oxygen,” “high-flow nasal oxygenation,” “high-flow nasal cannula,” “transnasal humidified rapid-insufflation ventilatory exchange,” “pre-oxygenation,” “apneic oxygenation,” and “OptiFlow.” References of articles and relevant meta-analyses were also reviewed to confirm that no study was missed.

2.2. Eligibility criteria and study quality assessment

Included studies met all the following criteria: subjects ≥ 18 years of age, uses of HFNO for pre-oxygenation, comparisons of high-flow nasal cannula and facemask, reporting outcomes of arterial partial pressure of oxygen (PaO₂), safe apnea time, oxygen desaturation during intubation, lowest peripheral capillary oxygen saturation (SpO₂) during intubation or patient comfort score, and articles published in peer-reviewed journals. We excluded observational studies, review articles or editorials, studies evaluating critically ill patients with respiratory failure, and studies not reporting outcomes of interest. Two authors (HCK and WCL) independently reviewed and collected data, including study design, characteristics of subjects, and study outcomes. The third blinded reviewer (YGC) resolved any disagreements between reviewers. The quality of randomized controlled trials was appraised by HCK and WCL using the Cochrane Handbook for Systematic Reviews of Interventions.[27] Any disagreement was resolved via group discussions.

2.3. Outcome measurement

Patients were classified into the HFNO group if they underwent pre-oxygenation using a high-flow nasal cannula with a flow of 100% oxygen > 30 L/minute.[1] Patients were classified into the FMO group if pre-oxygenation maneuver was performed using a standard anesthetic facemask with 100% oxygen. Primary outcome was the level of PaO₂ after pre-oxygenation. Secondary outcomes were safe apnea time, which was defined as the interval between start of apnea verified by capnography and SpO₂ reaching 90% to 95% or endotracheal tube in place,[10–12,16,18,20–22] arterial desaturation (SpO₂ below 90–95%) during intubation, lowest SpO₂ during intubation, and patient comfort score. Patient comfort score was graded by the numeric rating scale, ranging from 0 to 10. The ascertainment of safe apnea time and arterial desaturation were based on the definitions described in the primary studies.

2.4. Data synthesis and analysis

Data synthesis was performed using random-effects models and Mantel–Haenszel method to generate mean difference and risk ratio (RR) by using RevMan software, version 5.3 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark). The I² statistics were used to check for quantitative heterogeneity of results[28,29] and defines low heterogeneity with I² < 25%, moderate heterogeneity with I² between 25% and 50%, and high heterogeneity with I² > 50%. A funnel plot was used to assess a potential publication bias. Visual estimation was performed to examine the asymmetry of the funnel plot. We estimated and obtained the sample mean and standard deviation from the sample size, median, interquartile range, and/or range of the primary studies using Wan et al’s method.[29] Subgroup analyses by obese and non-obese people were conducted to compare the efficacy of HFNO and FMO in the 2 populations. As a sensitivity test, we excluded the studies of healthy volunteers (Pillai et al[9] and Hanouz et al[14]) to exclusively examine the efficacy of HFNO and FMO in surgical and anesthetized patients. A 2-sided significance level of 0.05 was used to assess statistically significant difference.

3. Results

The flow diagram of Preferred Reporting Items for Systematic Reviews and Meta-analyses is described in Fig. 1. The systemic review identified a total of 16 randomized controlled trials,[8–23]
which enrolled 1148 patients. Patients were divided into the HFNO group (n = 576) and FMO group (n = 572). Baseline characteristics of the included studies are listed in Table 1. Indications for pre-oxygenation were reported in all studies, including induction of anesthesia\cite{8,10–13,15–23} and healthy volunteers.\cite{9,14} Four studies evaluated obese patients for surgery.\cite{8,15,16,22} Two studies recruited healthy pregnant women who required tracheal intubation for elective cesarean section.\cite{20,23}

All studies used OptiFlow system (AIRVO 2; Fisher and Paykel Healthcare Ltd., New Zealand) for HFNO.\cite{8–23} HFNO was performed with a warmed and humidified flow of 100% oxygen with a rate of 30 to 70 L/minute\(^{-1}\) during pre-oxygenation. The nasal cannula flow was escalated to 50 to 70 L/minute\(^{-1}\) for apneic oxygenation in anesthetized patients.\cite{8,10–13,15–23} Lyons et al\cite{21} randomized patients into 3 groups, facemask, high-flow nasal cannula only, or high-flow nasal cannula plus a mouthpiece. We used the data of high-flow nasal cannula only for meta-analysis to reduce the heterogeneity of oxygenation method.\cite{21}

For FMO, 14 studies used a well-sealed facemask connected to an anesthetic circuit and allowed patients to breathe spontaneously with 100% oxygen flow of 6 to 15 L/minute\(^{-1}\).\cite{8,10–14,16–21,23} One study performed FMO by using ventilators with a 10 cm\(^2\) H\(_2\)O pressure support and 100% oxygen.\cite{15} One study used positive end-expiratory pressure (PEEP) of 7 cm H\(_2\)O for FMO.\cite{22} Heinrich et al\cite{8} divided participants into 3 groups, facemask without positive pressure, facemask with positive pressure, or high-flow nasal cannula. We used the data of facemask without positive pressure for meta-analysis.\cite{8} Duration of pre-oxygenation ranged from 3 to 7 minutes.

After apnea occurred, one study used a nasopharyngeal catheter to deliver oxygen at a flow of 12 L/minute\(^{-1}\).\cite{11} One study used a simple nasal cannula with 100% oxygen flow of 6 L/minute\(^{-1}\).\cite{20} Two studies used bag-mask ventilation.\cite{13,22} Other studies used a facemask to deliver 100% oxygen flow of 10 to 15 L/minute\(^{-1}\).\cite{8,10,12,15–19,21,23} Heinrich et al\cite{8} measured the PaO\(_2\) at 1, 3, 5, 7, and 8.5 minutes during pre-oxygenation, and we used the data of 3 minutes. Rosén et al\cite{22} measured the PaO\(_2\) at 2.5 and 5.0 minutes during pre-oxygenation, and we used the data of 2.5 minutes.

3.1. Study quality assessment

Table 2 shows the assessment of study quality: 14 studies conducted a high-quality randomization with allocation...
| Author                        | Country            | Characteristics of subjects                                                                 | No. of subjects | Protocol of HFNO                      | Protocol of FMO                      | Duration of pre-oxygenation | Apneic oxygenation in HFNO | Apneic oxygenation in FMO | Neuro-muscular blocker | Patient position |
|------------------------------|--------------------|-------------------------------------------------------------------------------------------|-----------------|---------------------------------------|--------------------------------------|-----------------------------|-----------------------------|---------------------------|-------------------------|----------------------|
| Heinrich et al, 2014         | Germany            | Morbidly obese patients undergoing RSI for laparoscopic bariatric surgery                   | 11              | HFNO: 11                               | FMO: 11                              | 7min                        | OptiFlow using a flow of 100% oxygen 50 L/min - with mouth closed | 100% oxygen flow of 12L/min - using a facemask | Succinylcholine           | 30° head up          |
| Pillai et al, 2016           | United Kingdom     | Healthy volunteers                                                                         | 10              | HFNO: 10                               | FMO: 10                              | 3min                        | NA                          | NA                        | NA                      | 45° head up          |
| Mir et al, 2017              | United Kingdom     | Patients requiring RSI for emergency surgery                                                | 20              | HFNO: 20                               | FMO: 20                              | 3min                        | OptiFlow using a flow of 100% oxygen 70 L/min - | 100% oxygen flow of 12L/min - using a facemask | Rocuronium 1mgkg⁻¹       | Not reported         |
| Pillai et al, 2016           | India              | Patients requiring intubation for neurosurgical operation                                  | 5               | HFNO: 5                                | FMO: 5                               | 3min                        | OptiFlow using a flow of 100% oxygen 70 L/min - | 100% oxygen flow of 12L/min - using a nasopharyngeal catheter | Atracurium 0.5mgkg⁻¹     | NR                   |
| Pillai et al, 2016           | United Kingdom     | Healthy volunteers                                                                         | 50              | HFNO: 50                               | FMO: 50                              | 3min                        | NA                          | NA                        | Succinylcholine           | 25° head up          |
| Wouc’h et al, 2019           | France             | Obese patients requiring RSI for elective surgery                                          | 50              | HFNO: 50                               | FMO: 50                              | 4min                        | OptiFlow using a flow of 100% oxygen 60 L/min - | Pressure support mode with a 10 cm H₂O pressure support, 100% oxygen | Succinylcholine, rocuronium, or none | Ramped position |
| Wong et al, 2019             | Canada             | Obese patients requiring intubation for elective surgery                                   | 20              | HFNO: 20                               | FMO: 20                              | 3min                        | OptiFlow using a flow of 100% oxygen 70 L/min - | 100% oxygen flow of 15L/min - using a facemask | Rocuronium 0.6mgkg⁻¹     | 30° head up          |
| Troemy et al, 2021           | France             | Patients requiring intubation for an elective surgical procedure                           | 30              | HFNO: 30                               | FMO: 30                              | ≥3min                       | OptiFlow using a flow of 100% oxygen 70 L/min - | 100% oxygen using a facemask | Rocuronium 0.6mgkg⁻¹     | Sniffing position    |
| Hua et al, 2020              | China              | Elderly patients requiring intubation or tracheal mask for general anesthesia              | 28              | HFNO: 30                               | FMO: 28                              | 5min                        | OptiFlow using a flow of 100% oxygen 70 L/min - | 100% oxygen flow of 10L/min - using a facemask | Cisatracurium 0.1–0.2mgkg⁻¹ | Supine position       |
| Sjöblom et al, 2021          | Sweden             | Patients requiring RSI for emergency surgery                                                | 174             | HFNO: 174                              | FMO: 175                             | ≥3min                       | OptiFlow using a flow of 100% oxygen 70 L/min - | 100% oxygen flow of 10L/min - using a facemask | Succinylcholine, rocuronium, or combination | Reverse Trendelenburg position |
| Osman et al, 2021            | Egypt              | Healthy parturients requiring intubation for elective oesarean section                     | 50              | HFNO: 50                               | FMO: 50                              | 3min                        | OptiFlow using a flow of 100% oxygen 50 L/min - | Simple nasal cannula with 100% oxygen flow of 6L/min - | Atracurium 0.5mgkg⁻¹     | Ramped position with left lateral tilt |
| Lyons et al, 2021            | Ireland            | Patients requiring intubation for an elective surgical procedure                           | 25              | HFNO: 25                               | FMO: 26                              | ≥3min                       | OptiFlow using a flow of 100% oxygen 50 L/min - | 100% oxygen flow of 15L/min - using a facemask | Rocuronium 1.0mgkg⁻¹     | NR                   |

(continued)
3.2. PaO₂ after pre-oxygenation

When data were pooled across studies, the analysis showed that HFNO achieved a higher PaO₂ after pre-oxygenation compared with FMO, mean difference: 64.86 mm Hg (95% CI: 32.33–97.40, P < .0001; I² = 79%) (Fig. 2). The difference was significant both in obese subjects (38.80, 95% CI: 7.22–70.37, P = .02; I² = 0%) and non-obese subjects (71.23, 95% CI: 33.07–109.39, P = .0003; I² = 80%). Funnel plot revealed no obvious publication bias. The difference in the PaO₂ between HFNO and FMO in surgical patients is shown in the Figure S1, Supplemental Digital Content, http://links.lww.com/MD2/A939.

3.3. Safe apnea time

Safe apnea time was longer in patients using HFNO compared with FMO, mean difference: 131.03 seconds (95% CI: 59.39–202.66, P < .0001; I² = 97%) (Fig. 3A). The safe apnea time was significantly greater in HFNO compared with FMO both in obese patients (119.17, 95% CI: 36.96–201.38, P = .004; I² = 93%) and non-obese patients (137.00, 95% CI: 27.75–246.26, P = .01; I² = 98%). Funnel plot revealed no obvious publication bias.

3.4. Arterial desaturation during intubation

There was no difference in the risk of arterial desaturation during intubation between HFNO and FMO in all studies (RR: 0.54, 95% CI: 0.27–1.08, P = .08; I² = 18%) (Fig. 3B). However, there was a trend towards a lower risk of desaturation in the non-obese patients (RR: 0.44, 95% CI: 0.19–1.01, P = .05; I² = 21%). Funnel plot revealed no obvious publication bias.

3.5. Lowest SpO₂ during intubation

There was no difference in the lowest SpO₂ during intubation between 2 groups, mean difference: 0% (95% CI: −2.00–2.00, P = 1.00; I² = 82%) (Fig. 3C).

3.6. Patient comfort score

Patients undergoing HFNO had a higher comfort score compared with FMO, mean difference: 1.00 (95% CI: 0.46–1.54, P = .0003; I² = 0%) (Fig. 3D). The results of sensitivity test are shown in the Figure S2, Supplemental Digital Content, http://links.lww.com/MD2/A940.

4. Discussion

This study was the first meta-analysis of randomized controlled trials to specifically compare the efficacy of high-flow nasal cannula and standard facemask in pre-oxygenation for anesthetized patients. Our analyses showed that HFNO achieved a higher PaO₂ after pre-oxygenation, extended safe apnea time, and improved patient comfort compared with FMO. The risk of desaturation and lowest SpO₂ during intubation were similar between 2 techniques. These results suggest that HFNO appears to be a practicable method for pre-oxygenation in the setting of GA.
### Table 2
Study quality assessment of randomized controlled trials.

| Author                  | Random allocation | Allocation concealment | Blinding | Any loss to follow-up | Analysis                                           |
|-------------------------|-------------------|------------------------|----------|------------------------|---------------------------------------------------|
| Heinrich et al, 2014    | PY                | NR                     | Any      | ITT: PY for efficacy outcomes | Data for primary efficacy assessment available for 100% of randomized patients |
| Pillai et al, 2016      | DY                | PY                     | CN       | ITT: DY for efficacy outcomes | Data for primary efficacy assessment available for 100% of randomized patients |
| Mir et al, 2017         | DY                | DY                     | CN       | ITT: DY for efficacy outcomes | Data for primary efficacy assessment available for 100% of randomized patients |
| Rajan et al, 2018       | DY                | DY                     | CN       | ITT: DY for efficacy outcomes | Data for primary efficacy assessment available for 100% of randomized patients |
| Lodenius et al, 2018    | PY                | CN                     | CN       | ITT: PN for efficacy outcomes | Data for primary efficacy assessment available for 98.8% of randomized patients |
| Ng et al, 2018          | DY                | DY                     | CN       | ITT: PN for efficacy outcomes | Data for primary efficacy assessment available for 96.0% of randomized patients |
| Hanouz et al, 2019      | PY                | PY                     | CN       | ITT: DY for efficacy outcomes | Data for primary efficacy assessment available for 100% of randomized patients |
| Vourc'h et al, 2019     | DY                | DY                     | CN       | ITT: DY for efficacy outcomes | Data for primary efficacy assessment available for 100% of randomized patients |
| Wong et al, 2019        | DY                | DY                     | CN       | ITT: DY for efficacy outcomes | Data for primary efficacy assessment available for 100% of randomized patients |
| Tremey et al, 2020      | DY                | PY                     | CN       | ITT: DY for efficacy outcomes | Data for primary efficacy assessment available for 98.4% of randomized patients |
| Hua et al, 2020         | DY                | PY                     | CN       | ITT: PN for efficacy outcomes | Data for primary efficacy assessment available for 98.3% of randomized patients |
| Sjöblom et al, 2021     | DY                | DY                     | CN       | ITT: PN for efficacy outcomes | Data for primary efficacy assessment available for 99.7% of randomized patients |

(continued)
Difficult Airway Society 2015 guidelines recommend the use of nasal cannula in pre-oxygenation,[4] which is primarily based on the studies before 2010 (with nasal insufflation of oxygen at a flow of only 5 L/minute) or observational studies.[32] In the recent decade, randomized controlled trials have shown that transnasal humidified high-flow oxygen with a rate up to 70 L/minute prolongs safe apnea time during tracheal intubation for severely hypoxemic patients.[24,25,32,33] Although guidelines recommend the use of nasal cannula in patients at high risk of difficult airway, its efficacy as a pre-oxygenation method has not been thoroughly evaluated.[4] Our study provided the evidence that HFNO with apneic oxygenation enhances PaO₂ better and is not inferior to FMO in preventing hypoxia during tracheal intubation. For patients with an anticipated difficult airway, studies have demonstrated that high-flow nasal oxygen therapy improved oxygen saturation and reduced the risk of desaturation during awake fiberoptic tracheal intubation compared with facemask ventilation.[34,35] These results suggest that HFNO may serve as an ideal pre-oxygenation technique for performing potentially difficult intubations.

There are 2 physiological mechanisms underlying the benefits of high-flow nasal oxygen therapy in oxygenation and gaseous exchanges.

Table 2 (continued).

| Author           | Random allocation | Allocation concealment | Blinding | Any loss to follow-up | Analysis                                                                 |
|------------------|-------------------|------------------------|----------|-----------------------|--------------------------------------------------------------------------|
| Osman et al, 2021[20] | DY                | DY                     | Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR. | CN ITT: PN for efficacy outcomes | Data for primary efficacy assessment available for 94.3% of randomized patients |
| Lyons et al, 2021[21] | DY                | DY                     | Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR. | CN ITT: PN for efficacy outcomes | Data for primary efficacy assessment available for 91.1% of randomized patients |
| Rosén et al, 2021[22] | DY                | DY                     | Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR. | CN ITT: PN for efficacy outcomes | Data for primary efficacy assessment available for 90.0% of randomized patients |
| Zhou et al, 2021[23] | DY                | DY                     | Patients: CN; caregivers: CN; data collectors: NR; adjudicators: NR; data analysis: NR. | CN ITT: PN for efficacy outcomes | Data for primary efficacy assessment available for 85.0% of randomized patients |

CN = certainly no, DY = definitely yes, ITT = intention to treat, NR = not reported, PN = probably no, PY = probably yes.

Figure 2. Forest plot of arterial partial pressure of oxygen (mm Hg) after pre-oxygenation between HFNO and FMO groups. CI = confidence interval, FMO = facemask oxygenation, HFNO = high-flow nasal oxygenation.
### Figure 3.

Forest plot of (A) safe apnea time (second), (B) arterial desaturation during intubation, (C) lowest peripheral capillary oxygen saturation during intubation (%), and (D) patient comfort score (numeric rating scale, 0–10) between HFNO and FMO groups. CI = confidence interval, FMO = facemask oxygenation, HFNO = high-flow nasal oxygenation, M–H = Mantel–Haenszel.

#### Table A

| Study or Subgroup | HFNO | SD | Total | M–H | Random, 95% CI | Weight | Risk Ratio M–H, Random, 95% CI | Year |
|-------------------|------|----|-------|-----|----------------|--------|--------------------------------|------|
| Non-obese subjects |      |    |       |     |                |        |                                 |      |
| Mir 2016          | 248  | 71 | 20    | 123 | 55             | 20     | 14.4%                          | 125.00 [85.64, 164.36] |
| Rajan 2018        | 796  | 43 | 5     | 444 | 55             | 5      | 13.6%                          | 352.00 [292.16, 411.82] |
| Lodenius 2018     | 128  | 42 | 40    | 125 | 51             | 39     | 14.8%                          | 3.00 [17.63, 23.61]     |
| Hua 2020          | 600  | 0  | 30    | 477 | 28             | 28     | Not estimable                  |                 |
| Osman 2021        | 420  | 80 | 50    | 240 | 53             | 50     | 14.7%                          | 180.00 [153.40, 206.66] |
| Lyons 2021        | 344  | 106| 25    | 315 | 137            | 26     | 13.3%                          | 29.00 [18.98, 46.08]    |
| Subtotal (95% CI) | 270  | 168|       |     |                |        |                                 |      |
| Heterogeneity: $I^2 = 19488.67, CH^2 = 192.17, df = 4$ ($P < 0.00001$); $I^2 = 98%$ |
| Test for overall effect: $Z = 2.46$ ($P = 0.01$) |

#### Table B

| Study or Subgroup | HFNO | SD | Total | M–H | Random, 95% CI | Weight | Risk Ratio M–H, Random, 95% CI | Year |
|-------------------|------|----|-------|-----|----------------|--------|--------------------------------|------|
| Obese subjects    |      |    |       |     |                |        |                                 |      |
| Youn'Ch 2019      | 5    | 50 | 5     | 50  | 21.7%          | 12     | 0.20                           | 0.09 [0.01, 1.64] 2019 |
| Rosén 2021        | 127  | 36 | 1     | 16  | 4.5%           | 12     | 0.07                           | 0.01 [0.01, 6.21] 2021 |
| Subtotal (95% CI) | 122  | 24 | 5     | 50  |                |        |                                 |      |
| Heterogeneity: $I^2 = 0.00, CH^2 = 0.80, df = 1$ ($P = 0.37$); $I^2 = 0%$ |
| Test for overall effect: $Z = 0.02$ ($P = 0.98$) |

#### Table C

| Study or Subgroup | HFNO | SD | Total | M–H | Random, 95% CI | Weight | Risk Ratio M–H, Random, 95% CI | Year |
|-------------------|------|----|-------|-----|----------------|--------|--------------------------------|------|
| Obese subjects    |      |    |       |     |                |        |                                 |      |
| Youn'Ch 2019      | 97   | 5  | 50    | 99  | 2               | 50     | 35.0%                          | -2.00 [-1.49, -0.51] 2019 |
| Wong 2019         | 91   | 4  | 20    | 88  | 5               | 20     | 23.4%                          | 3.00 [0.19, 5.81]      |
| Subtotal (95% CI) | 188  | 9  | 70    | 178 |                |        |                                 |      |
| Heterogeneity: $I^2 = 891.92, CH^2 = 235.88, df = 6$ ($P < 0.00001$); $I^2 = 97%$ |
| Test for subgroup differences: $CH^2 = 1.29, df = 1$ ($P = 0.26$); $I^2 = 22.5%$ |

#### Table D

| Study or Subgroup | HFNO | SD | Total | M–H | Random, 95% CI | Weight | Risk Ratio M–H, Random, 95% CI | Year |
|-------------------|------|----|-------|-----|----------------|--------|--------------------------------|------|
| Obese subjects    |      |    |       |     |                |        |                                 |      |
| Sjöholm A 2021    | 99   | 3  | 174   | 99  | 3              | 175    | 41.6%                          | 0.00 [-0.63, 0.63]     |
| Subtotal (95% CI) | 174  | 3  |       |     |                |        |                                 |      |
| Heterogeneity: Not applicable |
| Test for overall effect: $Z = 0.00$ ($P = 1.00$) |

#### Table E

| Study or Subgroup | HFNO | SD | Total | M–H | Random, 95% CI | Weight | Risk Ratio M–H, Random, 95% CI | Year |
|-------------------|------|----|-------|-----|----------------|--------|--------------------------------|------|
| Obese subjects    |      |    |       |     |                |        |                                 |      |
| Youn'Ch 2019      | 97   | 5  | 50    | 99  | 2              | 50     | 35.0%                          | -2.00 [-1.49, -0.51] 2019 |
| Wong 2019         | 91   | 4  | 20    | 88  | 5              | 20     | 23.4%                          | 3.00 [0.19, 5.81]      |
| Subtotal (95% CI) | 188  | 9  | 70    | 178 |                |        |                                 |      |
| Heterogeneity: $I^2 = 891.92, CH^2 = 235.88, df = 6$ ($P < 0.00001$); $I^2 = 97%$ |
| Test for subgroup differences: $CH^2 = 1.29, df = 1$ ($P = 0.26$); $I^2 = 22.5%$ |

#### Table F

| Study or Subgroup | HFNO | SD | Total | M–H | Random, 95% CI | Weight | Risk Ratio M–H, Random, 95% CI | Year |
|-------------------|------|----|-------|-----|----------------|--------|--------------------------------|------|
| Obese subjects    |      |    |       |     |                |        |                                 |      |
| Youn'Ch 2019      | 97   | 5  | 50    | 99  | 2              | 50     | 35.0%                          | -2.00 [-1.49, -0.51] 2019 |
| Wong 2019         | 91   | 4  | 20    | 88  | 5              | 20     | 23.4%                          | 3.00 [0.19, 5.81]      |
| Subtotal (95% CI) | 188  | 9  | 70    | 178 |                |        |                                 |      |
| Heterogeneity: $I^2 = 891.92, CH^2 = 235.88, df = 6$ ($P < 0.00001$); $I^2 = 97%$ |
| Test for subgroup differences: $CH^2 = 1.29, df = 1$ ($P = 0.26$); $I^2 = 22.5%$ |
exchange. First, HFNO generates a low level of positive pressure, mean 2.7 cm H2O at a gas flow rate of 35 L min⁻¹ in healthy adults.⁶ HFNO for apneic oxygenation extends safe apnea time compared with conventional oxygen therapy.⁴,⁶,¹⁰,¹¹,¹₆,¹₉,³⁴,³⁶ Second, transnasal humidified rapid-insufflation ventilatory exchange in HFNO may facilitate gaseous exchange and enhance carbon dioxide clearance through the interaction between cardiogenic oscillations and supraglottic flow vortices created by nasal gas flow.⁷,³⁶ By contrast, a recent randomized trial refuted the advantage of HFNO over spontaneous ventilation in carbon dioxide washout among adults undergoing micro-laryngoscopy.¹⁷ More studies are needed to clarify the efficacy of HFNO in improving gaseous exchange during apnea.

Patients with obesity have reduced respiratory reserve due to their lower vital capacity, functional residual capacity, and lung compliance.³⁸ The apnea time of SpO₂ dropping to 90% after FMO is <3 minutes in obese patients compared with 6 minutes in the non-obese.³⁹ The greater risk of oxygen desaturation in obese patients warrants further development of pre-oxygenation techniques for anesthesia care. However, it remains inconclusive whether HFNO is superior to FMO in preventing perioperative desaturation in obese patients.¹,⁸,¹₅,¹₆,²²,⁴⁰–⁴² Heinrich et al⁹ reported that HFNO for 3 minutes generated the highest PaO₂ compared with oxygen insufflation or continuous positive airway pressure via a facemask. Similarly, HFNO prolonged the safe apnea time to SpO₂ 95% by 76 seconds and enhanced minimum SpO₂ in morbidly obese patients.¹⁶ On the contrary, Vourc’h et al¹⁵ showed that HFNO produced a lower end-tidal oxygen level after tracheal intubation and carried a higher risk of desaturation. Rosén et al²² showed that FMO was superior to HFNO in enhancing end-tidal fraction of oxygen. The use of HFNO after tracheal extubation was demonstrated to prevent hypoxemia among obese patients following bariatric surgery in one study⁴⁰ but not another.⁴¹ In propofol sedation for colonoscopy, the desaturation rate was similar between HFNO and standard nasal cannula.¹⁴² These disagreements may come from the discrepancies in the oxygenation protocol and study outcomes. Vourc’h et al¹⁵ used pressure support and Rosén et al²² used PEEP for FMO. Furthermore, the inconsistent use of neuromuscular blocking drugs in the study of Vourc’h et al¹⁵ might also affect the efficacy of HFNO. The use of neuromuscular blocking agents is associated with a higher success rate of tracheal intubation.⁴³ Intubation without neuromuscular blockade may increase the risk of oxygen desaturation, which potentially underestimates the potential benefit of HFNO in preventing desaturation. More studies are warranted to elucidate the optimal strategy of applying HFNO to peri-procedural oxygenation for obese patients.

A simple facemask typically provides supplemental oxygen with a flow rate of 5 to 10 L min⁻¹ and a fraction of inspired oxygen of 0.35 to 0.55.¹⁴⁴ The oxygen flow rate >10 L min⁻¹ cannot further increase the fraction of inspired oxygen in a simple facemask.⁴⁴ In addition, the facemask is necessarily removed during tracheal intubation and therefore cannot deliver an oxygen flow regardless of the flow rate. Based on our analytical results, we reason that FMO with an oxygen flow >10 L min⁻¹ can hardly outperform HFNO in terms of PaO₂ and safe apnea time. More studies are needed to evaluate the efficacy of HFNO and FMO with varying oxygen flow rates, particularly for patients with poor respiratory reserve.

Attention to some limitations of this study is needed. First, the number of subjects enrolled in the meta-analysis was only modest, and some subgroup analyses may have inadequate statistical power. Second, the outcomes of interest are not available for all included studies. Third, the heterogeneity of results was high in some analyses, which may relate to the variations in characteristic of subjects (healthy volunteers or patients), protocol of oxygenation (oxygen flow rate, use of pressure support or PEEP, and use of neuromuscular blocking agents or not), and definitions of outcomes. Fourth, given that the individual date of included clinical trials are unavaiable, we could not compare the efficacy of HFNO and FMO in some subgroups, such as men or women and people with different body mass indexes.

In conclusion, HFNO for pre-oxygenation achieved a higher PaO₂, extended safe apnea time, and improved patient comfort compared with standard FMO. The risk of desaturation and lowest SpO₂ during intubation were similar between 2 methods. These results suggest that HFNO appears to be an ideal and useful technique for pre-oxygenation in the setting of GA. HFNO may be considered as an alternative to standard FMO, especially for patients at risk of difficult intubation.

Author contributions

Conceptualization: Chun-Cheng Li, Ying-Husan Tai.
Data curation: Hsien-Cheng Kuo, Wan-Chi Liu.
Formal analysis: Hsien-Cheng Kuo.
Funding acquisition: Ying-Husan Tai.
Investigation: Ying-Husan Tai.
Resources: Yih-Giun Cheng.
Supervision: Ying-Husan Tai.
Validation: Yih-Giun Cheng.
Writing – original draft: Hsien-Cheng Kuo, Wan-Chi Liu.
Writing – review & editing: Chun-Cheng Li, Jui-Tai Chen, Hsiang-Ling Wu, Ying-Husan Tai.

References

[1] Nimmagadda U, Salem MR, Crystal GJ. Preoxygenation: physiologic basis, benefits, and potential risks. Anesth Analg 2017;124:507–17.
[2] Apfelbaum JL, Hagberg CA, Connis RT, et al. 2012 American Society of Anesthesiologists practice guidelines for management of the difficult airway. Anesthesiology 2022;136:31–81.
[3] Taha SK, El-Khabth MF, Baraka AS, et al. Effect of suxamethonium vs rocuronium on onset of oxygen desaturation during apnoea following rapid sequence induction. Anaesthesia 2010;65:538–61.
[4] Frerck C, Mitchell VS, McNarry AF, et al. Difficult Airway Society 2015 guidelines for management of unanticipated difficult intubation in adults. Br J Anaesth 2015;115:827–48.
[5] Spoletini G, Alotabi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. Chest 2013;148:253–61.
[6] Parke R, McGuinness S, Eccleston M. Nasal high-flow therapy delivers low level positive airway pressure. Br J Anaesth 2009;103:886–90.
[7] Hermez LA, Spence CJ, Payton MJ, Nouareï SAR, Patel A, Barnes TH. A physiological study to determine the mechanism of carbon dioxide clearance during apnoea when using transnasal humidified rapid insufflation ventilatory exchange (THRIVE). Anaesthesia 2019;74:441–9.
[8] Heinrich S, Horbach T, Stubner B, Prottengeier J, Irouschek A, Schmidt J. Benefits of heated and humidified high flow nasal oxygen for preoxygenation in morbidly obese patients undergoing bariatric surgery: a randomized controlled study. J Obes Bariatrics 2014;1:7.
[9] Pillai A, Daga V, Lewis J, Mahmoud M, Musnabhi M, Bogod D. High-flow humidified nasal oxygenation vs. standard face mask oxygenation. Anaesthesia 2016;71:1280–3.
[10] Mir F, Patel A, Iqbal R, Cecconi M, Nouareï SA. A randomised controlled trial comparing transnasal humidified rapid insufflation ventilatory exchange (THRIVE) pre-oxygenation with facemask pre-oxygenation in patients undergoing rapid sequence induction of anaesthesia. Anaesthesia 2017;72:439–43.
[11] Rajan S, Joseph N, Tosh P, Kadapamannil D, Paul J, Kumar L. Effectiveness of transnasal humidified rapid-insufflation ventilatory exchange versus traditional preoxygenation followed by apneic oxygenation in delaying desaturation during apnoea: a preliminary study. Indian J Anaesth 2018;62:202–7.

[12] Lodénius Å, Piehl J, Östlund A, Ullman J, Jonsson Fagerlund M. Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) vs. facemask breathing pre-oxygenation for rapid sequence induction in adults: a prospective randomised non-blinded clinical trial. Anaesthesia 2018;73:564–71.

[13] Ng I, Kriess R, Mezzavia P, et al. The use of transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) for pre-oxygenation in neurosurgical patients: a randomised controlled trial. Anaesthesia Intensive Care 2018;46:360–7.

[14] Hanouz JL, Lhermitte D, Gérard JL, Fischer MO. Comparison of pre-oxygenation using spontaneous breathing through face mask and high-flow nasal oxygen: a randomised controlled crossover study in healthy volunteers. Eur J Anaesthesiol 2019;36:333–41.

[15] Vourc’h M, Baud G, Feuillet F, et al. High-flow nasal cannulae versus non-invasive ventilation for preoxygenation of obese patients: the PREOPTIPOP randomized trial. EClinicalMedicine 2019;13:112–9.

[16] Wong DT, DallaLore A, Singh KP, et al. High-flow nasal oxygen improves safe apneic time in morbidly obese patients undergoing general anaesthesia: a randomized controlled trial. Anesth Analg 2019;129:1130–6.

[17] Tremey B, Squara P, De Labarre H, et al. Hands-free induction of general anaesthesia: a randomised pilot study comparing usual care and high-flow nasal oxygen. Minerva Anestesiol 2020;86:1135–42.

[18] Hua Z, Liu Z, Li Y, Zhang H, Yang M, Zuo M. Transnasal humidified rapid insufflation ventilatory exchange vs. facemask oxygenation in elderly patients undergoing general anaesthesia: a randomised controlled trial. Sci Rep 2020;10:3745.

[19] Sjöblom A, Broms J, Hedberg M, et al. Pre-oxygenation using high-flow nasal oxygen vs. tight facemask during rapid sequence induction. Anaesthesia 2018;73:938–44.

[20] Zhou S, Zhou Y, Cao X, et al. The effectiveness of transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) for pre-oxygenation in critically ill patients in the intensive care unit: a systematic review and meta-analysis. Sci Rep 2020;10:5745.

[21] Hua Z, Liu Z, Li Y, Zhang H, Yang M, Zuo M. Transnasal humidified rapid insufflation ventilatory exchange vs. facemask oxygenation in elderly patients undergoing general anaesthesia: a randomized controlled trial. Anesth Analg 2019;129:1130–6.

[22] Ramachandran SK, Cosnowski A, Shanks A, Turner CR. Apneic oxygenation during prolonged laryngoscopy in obese patients: a randomized, controlled trial of nasal oxygen administration. J Clin Anesth 2010;22:164–8.

[23] Taha SK, Siddik-Sayyid SM, El-Khathib MF, Dagher CM, Hakki MA, Baraka AS. Nasopharyngeal oxygen insufflation following pre-oxygenation using the four breath deep technique. Anaesthesia 2006;61:427–30.

[24] Miguel-Montanes R, Hajage D, Messika J, et al. Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild-to-moderate hypoxemia. Crit Care Med 2015;43:574–83.

[25] Vourc’h M, Asfar P, Volteau C, et al. High-flow nasal cannula oxygen during endotracheal intubation in hypoxemic patients: a randomized controlled clinical trial. Intensive Care Med 2015;41:1538–48.

[26] Ahmad I, El-Boghdady K, Bhagrat R, et al. Difficult Airway Society guidelines for awake tracheal intubation (ATI) in adults. Anaesthesia 2020;75:509–28.

[27] Wu CN, Xia LZ, Li KH, et al. High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial. Br J Anaesth 2020;125:e166–8.

[28] Patel A, Nouraei SA. Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE): a physiological method of increasing apnoea time in patients with difficult airways. Anaesthesia 2015;70:323–9.

[29] Booth AWG, Vidhani K, Lee PK, et al. The effect of high-flow nasal oxygen on carbon dioxide accumulation in apneic or spontaneously breathing adults during airway surgery: a randomized-controlled trial. Anesth Analg 2021;133:133–41.

[30] Behazin N, Jones SB, Cohen RI, Loring SH. Respiratory restriction and elevated pleural and esophageal pressures in morbid obesity. J Appl Physiol 2010;108:212–8.

[31] Jense HG, Dubin SA, Silverstein PI, O’Leary-Escalas U. Effect of obesity on safe duration of apnea in anesthetized humans. Anesth Analg 1991;72:89–93.

[32] Ferrando C, Puig J, Serralta F, et al. High-flow nasal cannula oxygenation reduces postoperative hypoxemia in morbidly obese patients: a randomised controlled trial. Minerva Anestesiol 2019;85:1062–70.

[33] Fulton R, Millar JE, Merza M, et al. Prophylactic postoperative high flow nasal oxygen versus conventional oxygen therapy in obese patients undergoing bariatric surgery (OXYBAR Study): a pilot randomised controlled trial. Obes Surg 2021;31:4799–807.

[34] Riccio CA, Sarmiento S, Minhaajuddin A, Nasir D, Fox AA. High-flow versus standard nasal cannula in morbidly obese patients during colonoscopy: a prospective, randomized clinical trial. J Clin Anesth 2019;54:19–24.

[35] Mosier JM, Sakles JC, Stolz U, et al. Neuromuscular blockade improves first-attempt success for intubation in the intensive care unit. A propensity matched analysis. Ann Am Thorac Soc 2015;12:734–41.

[36] Hardavella G, Karampinis I, Frille A, Sreter K, Rousalova I. Oxygen devices and delivery systems. Breathe (Shef) 2019;15:e108–16.